Next Article in Journal
Gold Nanoparticle Mediated Multi-Modal CT Imaging of Hsp70 Membrane-Positive Tumors
Next Article in Special Issue
Impact of the Injection Site on Growth Characteristics, Phenotype and Sensitivity towards Cytarabine of Twenty Acute Leukaemia Patient-Derived Xenograft Models
Previous Article in Journal
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Previous Article in Special Issue
Multi-Modal PET and MR Imaging in the Hen’s Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial In Vivo Testing of Target-Specific Radioligands
Open AccessReview

Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(5), 1327; https://doi.org/10.3390/cancers12051327
Received: 13 April 2020 / Revised: 11 May 2020 / Accepted: 19 May 2020 / Published: 22 May 2020
(This article belongs to the Special Issue Patient-Derived Xenograft-Models in Cancer Research)
Pancreatic cancer (PC) is anticipated to be second only to lung cancer as the leading cause of cancer-related deaths in the United States by 2030. Surgery remains the only potentially curative treatment for patients with pancreatic ductal adenocarcinoma (PDAC), the most common form of PC. Multiple recent preclinical studies focus on identifying effective treatments for PDAC, but the models available for these studies often fail to reproduce the heterogeneity of this tumor type. Data generated with such models are of unknown clinical relevance. Patient-derived xenograft (PDX) models offer several advantages over human cell line-based in vitro and in vivo models and models of non-human origin. PDX models retain genetic characteristics of the human tumor specimens from which they were derived, have intact stromal components, and are more predictive of patient response than traditional models. This review briefly describes the advantages and disadvantages of 2D cultures, organoids and genetically engineered mouse (GEM) models of PDAC, and focuses on the applications, characteristics, advantages, limitations, and the future potential of PDX models for improving the management of PDAC. View Full-Text
Keywords: patient-derived xenograft; pancreatic cancer; preclinical study; genetically engineered mouse models; 3D organoids; preclinical drug evaluation; precision medicine patient-derived xenograft; pancreatic cancer; preclinical study; genetically engineered mouse models; 3D organoids; preclinical drug evaluation; precision medicine
Show Figures

Figure 1

MDPI and ACS Style

Garcia, P.L.; Miller, A.L.; Yoon, K.J. Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. Cancers 2020, 12, 1327.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop